Beating earnings and sales estimates by a notable margin suggests ANI Pharmaceuticals is performing well above expectations. This outperformance, especially when it exceeds analyst estimates by double-digit percentages, is typically viewed positively by investors and can lead to short-term stock price appreciation. The year-over-year growth in both earnings and sales further reinforces the company's upward trajectory, making it likely that investor sentiment will be positively impacted in the short term.